Navigation Links
Debate over safety of gene therapy trials focuses on issue of informed consent
Date:1/22/2008

New Rochelle, NY, January 22, 2008Can a patient who agrees to participate in a safety study of a gene therapy protocol give truly informed consent and understand the risks involved when the consent forms are highly technical and the physician or institution seeking their consent has a stake in the study and its outcome? The continuing debate over informed consent and the acknowledgement of risk and responsibility in gene therapy trials are the focus of a series of probing and provocative commentaries published in the January 2008 issue (Volume 19, Number 1) of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. The commentaries are available free online.

In the Editorial, James M. Wilson, MD, PhD, Editor-in-Chief and Head of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, at the University of Pennsylvania School of Medicine, in Philadelphia, calls on the gene therapy, regulatory, and research communities to re-explore the issue of informed consent as it relates to the safety of viral vector-based gene transfer therapies and the appropriateness of having physicians and others with an interest in the trials and their outcomes recruit patients and obtain the necessary informed consent.

I encourage the professional gene therapy societies and various related foundations to work together in the new year to undertake a critical review of the conduct of our clinical trials...it behooves us to get ahead of this issue and put in place more effective ways to assure that research subjects who courageously give of themselves can do so with a full and unbiased understanding of the risks and benefits of their participation, writes Dr. Wilson.

This issue of the Journal also includes five stimulating commentaries that discuss the key controversies related to patient recruitment and trial management. They explore the question of whether patients are able to comprehend the lengthy and often highly technical study descriptions and consent forms to the extent needed to make an informed decision about enrolling in a trial. The authors also present suggestions and innovative strategies for improving the recruitment and informed consent process.

Dr. Arthur Caplan, Professor of Bioethics, Chair of the Department of Medical Ethics, and Director of the Center for Bioethics at the University of Pennsylvania, authored a commentary entitled, If It Is Broken Shouldnt it Be Fixed? Informed Consent and Initial Clinical Trials of Gene Therapy. Another, entitled, Case of Leukaemia Associated with X-Linked Severe Combined Immunodeficiency Gene Therapy Trial in London, was prepared by the Board of the European Society of Gene and Cell Therapy, Executive Committee of the Clinigene Network of Excellence, and Executive of the Consort Integrated Project. Dr. Jeffrey Kahn, Director and Professor, Center for Bioethics, at the University of Minnesota Medical School, presents his perspectives in, Informed Consent in Human Gene Transfer Clinical Trials. Also contributing a commentary is Dr. Tomas Jose Silber, Chair of the Institutional Review Board and Director of the Office of Ethics at Childrens National Medical Center, in Washington, D.C. It is entitled, Human Gene Therapy, Consent, and the Realities of Clinical Research: Is It Time for a Research Subject Advocate? Ms. Suzanne Pattee, Vice President of Regulatory and Patient Affairs for the Cystic Fibrosis Foundation authored, Protections for Participants in Gene Therapy Trials: A Patients Perspective.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Related medicine news :

1. Health Insurance Industry Contributions to Politicians Block Regulation, Affordability in Health Care Debate, Says FTCR
2. Cincinnati Adoption Agency Invited to Participate in Values Voter Presidential Debate
3. Docs Debate Drugs vs. Surgery for Angina
4. Doctors Debate Drugs vs. Surgery for Angina
5. New study likely to fuel debate over annual physical exams
6. Post-Debate Statement From AARP Spokesperson Drew Nannis
7. Study fuels debate over whether exercise and body size influence ovarian cancer risk
8. Post-Debate Statement from AARP Board Member Joyce Payne
9. Long Term Care Leader Applauds Clinton for Bringing Critical Issue of Senior Care into the Presidential Debate
10. Mayo Clinic Proceedings provides forum for debate about capital punishment
11. Engaging 2008 Debate, Key Long Term Care Advocacy Groups Offer New Plan to Strengthen Nations Long Term and Post-Acute Care Delivery System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... NC (PRWEB) , ... April 28, 2017 , ... ... announce its new partnership with the Home Care Association of America (HCAOA). This ... and Private Duty Accreditation services, as well as discounts on Accreditation University (AU) ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Getting enough sleep affects much more than energy ... going just 19 hours without sleep can compromise motor reaction time, which can increase the ... Amica Insurance is sharing the following tips from the NSF to help you sleep better ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... Patel M.D. has joined the revolutionary endoscopic practice under Dr. Datta. Patel is ... Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta ...
(Date:4/28/2017)... ... ... People are starting to accept that hearing aids can be helpful and are ... had when great-grandpa wore his hearing aids years ago,” said Dr. Maura Marks, founder ... Speaker Series (NASS) segment. “He probably wore an iPod-size hearing aid on his ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... assisting the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates ... leading ERP expert that specializes in long-term care, Brooke Grove now has the ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
Breaking Medicine Technology: